kwic
acid
acid
right
off
ON
290
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for acid out of >500 occurrences
272943 occurrences (No.93 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to acid]
272943 occurrences (No.93 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 290) Acetyl-11-keto-β-boswellic acid (AKBA), a gum resin extract, possesses poor water-solubility that limits bioavailability and a high melting point making it difficult to successfully process into solid dispersions by fusion methods. |
| PMID:24329130 DOI:10.3109/03639045.2013.866142 |
| 2015 Drug development and industrial pharmacy |
| * Preparation of amorphous solid dispersions by rotary evaporation and KinetiSol Dispersing: approaches to enhance solubility of a poorly water-soluble gum extract. |
| - Acetyl-11-keto-β-boswellic acid (AKBA), a gum resin extract, possesses poor water-solubility that limits bioavailability and a high melting point making it difficult to successfully process into solid dispersions by fusion methods. The purpose of this study was to investigate solvent and thermal processing techniques for the preparation of amorphous solid dispersions (ASDs) exhibiting enhanced solubility, dissolution rates and bioavailability. Solid dispersions were successfully produced by rotary evaporation (RE) and KinetiSol® Dispersing (KSD). Solid state and chemical characterization revealed that ASD with good potency and purity were produced by both RE and KSD. Results of the RE studies demonstrated that AQOAT®-LF, AQOAT®-MF, Eudragit® L100-55 and Soluplus with the incorporation of dioctyl sulfosuccinate sodium provided substantial solubility enhancement. Non-sink dissolution analysis showed enhanced dissolution properties for KSD-processed solid dispersions in comparison to RE-processed solid dispersions. Variances in release performance were identified when different particle size fractions of KSD samples were analyzed. Selected RE samples varying in particle surface morphologies were placed under storage and exhibited crystalline growth following solid-state stability analysis at 12 months in comparison to stored KSD samples confirming amorphous instability for RE products. In vivo analysis of KSD-processed solid dispersions revealed significantly enhanced AKBA absorption in comparison to the neat, active substance. |
[
right
kwic]
(1)29  and |
(20)4 treatment |
(39)2 (FA) |
(58)2 from |
| (2)15 *null* | (21)3 (AA) |
(40)2 (PA) |
(59)2 hydrolysis |
| (3)11 in |
(22)3 (ALA) |
(41)2 (PLGA) |
(60)2 interactions |
| (4)10 phenethyl |
(23)3 (GABA) |
(42)2 (PLGA), |
(61)2 may |
| (5)10 phosphatase |
(24)3 (NEFA) |
(43)2 (SA) |
(62)2 nanoparticles |
| (6)9 is |
(25)3 changes |
(44)2 (SLA) |
(63)2 peptide |
| (7)8 was |
(26)3 decarboxylase |
(45)2 (TA) |
(64)2 proteins |
| (8)6 (HA) |
(27)3 etching |
(46)2 (TCA) |
(65)2 racemization |
| (9)6 reactive |
(28)3 levels |
(47)2 A |
(66)2 ratio |
| (10)5 as |
(29)3 metabolism |
(48)2 BSA |
(67)2 residues |
| (11)5 bacteria |
(30)3 on |
(49)2 Ig-superfamily |
(68)2 substances |
| (12)5 group |
(31)3 protein |
(50)2 Schiff |
(69)2 suppressive |
| (13)5 or |
(32)3 sequence |
(51)2 biosynthesis |
(70)2 synthetase |
| (14)5 synthesis |
(33)3 sequences |
(52)2 by |
(71)2 the |
| (15)5 to |
(34)3 status |
(53)2 changes, |
(72)2 therapy |
| (16)4 binding |
(35)3 were |
(54)2 composition |
(73)2 vitamin |
| (17)4 derivatives |
(36)2 (DHA) |
(55)2 contents |
|
| (18)4 for |
(37)2 (EDTA) |
(56)2 cycle |
|
| (19)4 solution |
(38)2 (EPA) |
(57)2 extract |
add keyword
--- WordNet output for acid ---